82 related articles for article (PubMed ID: 2839028)
1. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
[TBL] [Abstract][Full Text] [Related]
2. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
3. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
[TBL] [Abstract][Full Text] [Related]
4. Testicular function after local injection of 6-hydroxydopamine or norepinephrine in the golden hamster (Mesocricetus auratus).
Mayerhofer A; Amador AG; Steger RW; Bartke A
J Androl; 1990; 11(3):301-11. PubMed ID: 2117002
[TBL] [Abstract][Full Text] [Related]
5. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Huhtaniemi I; Nikula H; Rannikko S; Clayton R
J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
[TBL] [Abstract][Full Text] [Related]
6. Effect of a dopamine agonist on luteinizing hormone receptors, cyclic AMP production and steroidogenesis in rat Leydig cells.
Dirami G; Cooke BA
Toxicol Appl Pharmacol; 1998 Jun; 150(2):393-401. PubMed ID: 9653071
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract][Full Text] [Related]
8. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
9. Relationship between adult dark spermatogonia and secretory capacity of Leydig cells in cryptorchidism.
Zivkovic D; Bica DT; Hadziselimovic F
BJU Int; 2007 Nov; 100(5):1147-9; discussion 1149. PubMed ID: 17662083
[TBL] [Abstract][Full Text] [Related]
10. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
11. [Endocrinological profile of human spermatogenic impairment--evaluation of function of Leydig and Sertoli cells in vivo or in vitro studies].
Okuyama A; Nonomura N; Nakamura M; Namiki M; Matsuda M; Doi Y; Matsui T; Koh E; Kondoh N; Takeyama M
Hinyokika Kiyo; 1988 Nov; 34(11):1943-8. PubMed ID: 3149448
[TBL] [Abstract][Full Text] [Related]
12. Effect of estrogen treatment on testicular gonadotropin receptors in prostatic cancer patients.
Namiki M; Kitamura M; Nonomura N; Sugao H; Nakamura M; Okuyama A; Sonoda T; Matsumoto K
Arch Androl; 1987; 19(3):249-52. PubMed ID: 3142377
[TBL] [Abstract][Full Text] [Related]
13. Morphofunctional alterations in testicular cells of deslorelin-treated boars: an immunohistochemical study.
Kopera I; Tuz R; Kotula-Balak M; Schwarz T; Koczanowski J; Bilinska B
J Exp Zool A Ecol Genet Physiol; 2008 Mar; 309(3):117-26. PubMed ID: 18213611
[TBL] [Abstract][Full Text] [Related]
14. Postnatal changes in testicular gonadotropin receptors, serum gonadotropin, and testosterone concentrations and functional development of the testes in bulls.
Bagu ET; Cook S; Gratton CL; Rawlings NC
Reproduction; 2006 Sep; 132(3):403-11. PubMed ID: 16940281
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone receptor-mediated effects on initiation of spermatogenesis in gonadotropin-deficient (hpg) mice are replicated by testosterone.
Spaliviero JA; Jimenez M; Allan CM; Handelsman DJ
Biol Reprod; 2004 Jan; 70(1):32-8. PubMed ID: 12954730
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
Huhtaniemi I; Nikula H; Rannikko S
J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
[TBL] [Abstract][Full Text] [Related]
17. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
[TBL] [Abstract][Full Text] [Related]
18. Effects of in vivo and in vitro exposure to bromocriptine on testicular LH receptors and in vitro testosterone production in Syrian hamsters.
Amador AG; Bartke A
Rev Esp Fisiol; 1991 Sep; 47(3):121-7. PubMed ID: 1798854
[TBL] [Abstract][Full Text] [Related]
19. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
[TBL] [Abstract][Full Text] [Related]
20. Lack of a direct effect of gonadotropin hormone-releasing hormone agonist on human testicular steroidogenesis.
Rajfer J; Sikka SC; Swerdloff RS
J Clin Endocrinol Metab; 1987 Jan; 64(1):62-7. PubMed ID: 3023429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
